
Alopexx, Inc.
Symbol pendingFiledAlopexx, Inc. · Exchange pending · Research source · S-1/A · 2026-09-17 · Latest filing · S-1/A · 2026-11-06 SEC ↗
IPO research
As of the linked September 17, 2026 S-1/A, Alopexx has not completed its proposed IPO and is developing clinical-stage PNAG-targeted immune therapeutics.
Full source-backed summary
As of the September 17, 2026 S-1/A, Alopexx proposes a 3,000,000-share firm-commitment IPO at $10.00–$12.00 per share, but the registration statement remains preliminary and effectiveness, pricing, listing, trading and closing are unconfirmed.
As of the linked September 17, 2026 S-1/A, Alopexx has not completed its proposed IPO and is developing clinical-stage PNAG-targeted immune therapeutics.
- Business and development direction
Alopexx, Inc.
Current business Future development
Key risks
Risk 1
Neither AV0328 nor F598 is approved for commercial sale, and the company has not demonstrated completion of pivotal development or commercialization.
Risk 2
Regulators may require field efficacy trials rather than relying on surrogate OPK endpoints for AV0328.
Risk 3
The company relies on Bharat as a single vaccine CMO and may face costly, time-consuming transition if supply is interrupted.
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Offering quality | Some sourced inputs are available; a compatible set is needed for this view. Open filing ↗ |
| # | Institution | Underwriting allocation | Ratio | Shares |
|---|---|---|---|---|
| 1 | ThinkEquity LLC |
IPO CAPITAL QUALITY
Basis and evidence
S-1/A · 2026-09-17
As of the linked September 17, 2026 S-1/A, Alopexx has not completed its proposed IPO and is developing clinical-stage PNAG-targeted immune therapeutics.
Offering structure
| Measure | Reported value | Unit |
|---|---|---|
| Shares offered | 3,000,000 | Shares |
Source and calculation
Prospectus offering table; stated base scenario and source conditions Figures retain their stated source scenario and conditions.
Prospectus offering table; stated base scenario and source conditions
SEC table 8 row 2; source 199480:219857; SHA256 397ebe6f327438080add9f1f3b80d41d575c0b81807d291d5b71848035078430 ↗Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Use of proceeds | Source-linked structured inputs are not yet available. Open filing ↗ |
Dilution and valuation
Reported figures remain on their stated basis. Exact compatible price and whole-issuer post-offer inputs are required for calculations.
| Calculation | Shares | Value | Reference |
|---|---|---|---|
| Post-offer shares — as disclosed | 8,350,506 | — | |
| Post-offer shares — full option | 8,800,506 | — | |
| Capitalization shares — pro forma | 5,350,506 | — | |
| Capitalization shares — pro forma as adjusted | 8,350,506 | — | |
| Shares offered | 3,000,000 | — |
Basis and evidence ↗
Prospectus share summary; Common stock to be outstanding immediately after this Offering(1); 8,350,506 shares (8,800,506 shares if the underwriters exercise their over-allotment option in full).; selected security: shares; selected scenario: as disclosed; no inferred sum, conversion or equity value
Figures retain their stated source scenario and conditions.
Prospectus share summary; Common stock to be outstanding immediately after this Offering(1); 8,350,506 shares (8,800,506 shares if the underwriters exercise their over-allotment option in full).; selected security: shares; selected scenario: full option; no inferred sum, conversion or equity value
Figures retain their stated source scenario and conditions.
Capitalization share count; source stage: pro forma; Common Stock, $.0001 par value – 100,000,000 shares authorized, 5,155,081 shares issued and outstanding, 5,350,506 shares issued and outstanding pro forma, 8,350,506 shares issued and outstanding pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator
Figures retain their stated source scenario and conditions.
Capitalization share count; source stage: pro forma as adjusted; Common Stock, $.0001 par value – 100,000,000 shares authorized, 5,155,081 shares issued and outstanding, 5,350,506 shares issued and outstanding pro forma, 8,350,506 shares issued and outstanding pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator
Figures retain their stated source scenario and conditions.
Prospectus offering table; stated base scenario and source conditions
Prospectus offering table; stated base scenario and source conditions Figures retain their stated source scenario and conditions.
Share-count comparison
Compatible whole-issuer pre-offer and post-offer share counts are missing; holder, class-only or offered-share counts cannot substitute for them.
Source ↗IPO valuation scenario simulator
Source inputs required
Compatible source-bound inputs are not available; absence is not a non-disclosure finding.
Source ↗Source and calculation ↗
Compatible source-bound inputs are not available; absence is not a non-disclosure finding.
Compatible source-bound inputs are not available; absence is not a non-disclosure finding.
Compatible source-bound inputs are not available; absence is not a non-disclosure finding.
Compatible whole-issuer pre-offer and post-offer share counts are missing; holder, class-only or offered-share counts cannot substitute for them.
Each reported full-option, actual, diluted or class-specific case remains independent; no class sum or cross-date substitution is inferred.
Compatible source-bound inputs are not available; absence is not a non-disclosure finding.
The current source URL, accession, hash, proof variants, footnotes, input IDs and executable formulas remain attached. Missing source dates and precision gaps remain explicit.
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Ownership across stages | Some sourced inputs are available; a compatible set is needed for this view. Open filing ↗ |
- As of
- 2026-09-17
Relationship filters
Select for details · Alopexx, Inc.
Holdings and voting rights
Holder groups may overlap; these rows are not an additive ownership partition.
| Holder / measure | Shares | Ownership | Voting rights | Reference |
|---|---|---|---|---|
| Daniel VlockOwnership as disclosed | — | 56.1%Beneficial | — | Source statement; as stated; source predicate: will hold; primary source clause; source condition: assuming the conversion of the outstanding convertible notes into 195,425 shares of common stock and including shares underlying vested options exercisable within 60 days, and assuming no exercise of the underwriters’ over-allotment option; source scope: of our outstanding common stock, assuming the conversion of the outstanding convertible notes into 195,425 shares of common stock and including shares underlying vested options exercisable within 60; not an additive ownership partition |
| our executive officers, directors and 5% stockholdersOwnership as disclosed | — | approximately 97.84%Beneficial | — | Source statement; approximately ; source predicate: beneficially owned; primary source clause; full source conditions retained; source scope: of our voting stock as of June 30, 2026 and, upon the closing of this offering, that same group will continue to beneficially own approximately; not an additive ownership partition |
| our executive officers, directors and 5% stockholdersOwnership as disclosed | — | approximately 72.9%Beneficial | — | Source statement; approximately ; source predicate: will continue to beneficially own; primary source clause; full source conditions retained; source scope: of our outstanding voting stock; not an additive ownership partition |
| Daniel VlockVoting power | — | — | approximately 56.1%Voting power | Source statement; approximately ; source predicate: will beneficially own; primary source clause; source condition: assuming the conversion of the outstanding convertible notes into 195,425 shares of common stock and including shares underlying vested options exercisable within 60 days, and assuming no exercise of the underwriters’ over-allotment option; source scope: of the voting power of our common stock, assuming the conversion of the outstanding convertible notes into 195,425 shares of common stock and including shares underlying vested options exercisable wi; not an additive ownership partition |
| Daniel VlockBeneficial shares | 4,546,958 | — | — | Shares Beneficially OwnedBefore Offering; Number of Shares |
| Daniel VlockBeneficial shares | 4,684,334 | — | — | Shares Beneficially OwnedAfter Offering; Number of Shares |
| Peter WerthBeneficial shares | 535,623 | — | — | Shares Beneficially OwnedBefore Offering; Number of Shares |
| Peter WerthBeneficial shares | 568,967 | — | — | Shares Beneficially OwnedAfter Offering; Number of Shares |
| Dr. Gerald PierBeneficial shares | 627,850 | — | — | Shares Beneficially OwnedBefore Offering; Number of Shares |
| Dr. Gerald PierBeneficial shares | 627,850 | — | — | Shares Beneficially OwnedAfter Offering; Number of Shares |
| Gail H. CassellBeneficial shares | 11,600 | — | — | Shares Beneficially OwnedBefore Offering; Number of Shares |
| Gail H. CassellBeneficial shares | 11,600 | — | — | Shares Beneficially OwnedAfter Offering; Number of Shares |
| Richard CohenBeneficial shares | 11,600 | — | — | Shares Beneficially OwnedBefore Offering; Number of Shares |
| Richard CohenBeneficial shares | 11,600 | — | — | Shares Beneficially OwnedAfter Offering; Number of Shares |
| Ann MacDougallBeneficial shares | 11,600 | — | — | Shares Beneficially OwnedBefore Offering; Number of Shares |
| Ann MacDougallBeneficial shares | 11,600 | — | — | Shares Beneficially OwnedAfter Offering; Number of Shares |
| Daniel VlockBeneficial ownership | — | 87.2%Beneficial | — | Shares Beneficially OwnedBefore Offering; Percentage |
| Daniel VlockBeneficial ownership | — | 56.1%Beneficial | — | Shares Beneficially OwnedAfter Offering; Percentage |
| Peter WerthBeneficial ownership | — | 10.4%Beneficial | — | Shares Beneficially OwnedBefore Offering; Percentage |
| Peter WerthBeneficial ownership | — | 6.8%Beneficial | — | Shares Beneficially OwnedAfter Offering; Percentage |
| Dr. Gerald PierBeneficial ownership | — | 11.1%Beneficial | — | Shares Beneficially OwnedBefore Offering; Percentage |
| Dr. Gerald PierBeneficial ownership | — | 7.5%Beneficial | — | Shares Beneficially OwnedAfter Offering; Percentage |
| Gail H. CassellBeneficial ownership | — | 0.2%Beneficial | — | Shares Beneficially OwnedBefore Offering; Percentage |
| Gail H. CassellBeneficial ownership | — | 0.1%Beneficial | — | Shares Beneficially OwnedAfter Offering; Percentage |
| Richard CohenBeneficial ownership | — | 0.2%Beneficial | — | Shares Beneficially OwnedBefore Offering; Percentage |
| Richard CohenBeneficial ownership | — | 0.1%Beneficial | — | Shares Beneficially OwnedAfter Offering; Percentage |
| Ann MacDougallBeneficial ownership | — | 0.2%Beneficial | — | Shares Beneficially OwnedBefore Offering; Percentage |
| Ann MacDougallBeneficial ownership | — | 0.1%Beneficial | — | Shares Beneficially OwnedAfter Offering; Percentage |
| Christine de los ReyesBeneficial shares | 191,400 | — | — | Shares Beneficially OwnedBefore Offering; Number of Shares |
| Christine de los ReyesBeneficial shares | 191,400 | — | — | Shares Beneficially OwnedAfter Offering; Number of Shares |
| William W. ChinBeneficial shares | 281,213 | — | — | Shares Beneficially OwnedBefore Offering; Number of Shares |
| William W. ChinBeneficial shares | 281,213 | — | — | Shares Beneficially OwnedAfter Offering; Number of Shares |
| Thomas T. ThomasBeneficial shares | 328,425 | — | — | Shares Beneficially OwnedBefore Offering; Number of Shares |
| Thomas T. ThomasBeneficial shares | 328,425 | — | — | Shares Beneficially OwnedAfter Offering; Number of Shares |
| All Directors, Executive Officers and Director Nominees as a group (7 persons)Beneficial shares | 5,382,796 | — | — | Shares Beneficially OwnedBefore Offering; Number of Shares |
| All Directors, Executive Officers and Director Nominees as a group (7 persons)Beneficial shares | 5,520,172 | — | — | Shares Beneficially OwnedAfter Offering; Number of Shares |
| Christine de los ReyesBeneficial ownership | — | 3.6%Beneficial | — | Shares Beneficially OwnedBefore Offering; Percentage |
| Christine de los ReyesBeneficial ownership | — | 2.3%Beneficial | — | Shares Beneficially OwnedAfter Offering; Percentage |
| William W. ChinBeneficial ownership | — | 5.2%Beneficial | — | Shares Beneficially OwnedBefore Offering; Percentage |
| William W. ChinBeneficial ownership | — | 3.4%Beneficial | — | Shares Beneficially OwnedAfter Offering; Percentage |
| Thomas T. ThomasBeneficial ownership | — | 6%Beneficial | — | Shares Beneficially OwnedBefore Offering; Percentage |
| Thomas T. ThomasBeneficial ownership | — | 3.9%Beneficial | — | Shares Beneficially OwnedAfter Offering; Percentage |
| All Directors, Executive Officers and Director Nominees as a group (7 persons)Beneficial ownership | — | 89%Beneficial | — | Shares Beneficially OwnedBefore Offering; Percentage |
| All Directors, Executive Officers and Director Nominees as a group (7 persons)Beneficial ownership | — | 66.1%Beneficial | — | Shares Beneficially OwnedAfter Offering; Percentage |
Source and calculation ↗
Source statement; as stated; source predicate: will hold; primary source clause; source condition: assuming the conversion of the outstanding convertible notes into 195,425 shares of common stock and including shares underlying vested options exercisable within 60 days, and assuming no exercise of the underwriters’ over-allotment option; source scope: of our outstanding common stock, assuming the conversion of the outstanding convertible notes into 195,425 shares of common stock and including shares underlying vested options exercisable within 60; not an additive ownership partition
Upon completion of this offering, Daniel Vlock, our President and Chief Executive Officer, will hold a majority of the voting power of our capital stock through his beneficial ownership of 56.1% of our outstanding common stock, assuming the conversion of the outstanding convertible notes into 195,425 shares of common stock and including shares underlying vested options exercisable within 60 days, and assuming no exercise of the underwriters’ over-allotment option. As a result, we will be a “controlled company” under the listing requirements of the NYSE American, or the NYSE American Marketplace Rules. We do not intend to rely on any exemptions from the corporate governance requirements of the NYSE American Marketplace Rules. See the section titled “Management — Controlled Company Status.”
Source statement; approximately ; source predicate: beneficially owned; primary source clause; full source conditions retained; source scope: of our voting stock as of June 30, 2026 and, upon the closing of this offering, that same group will continue to beneficially own approximately; not an additive ownership partition
Prior to this offering, our executive officers, directors and 5% stockholders beneficially owned approximately 97.84% of our voting stock as of June 30, 2026 and, upon the closing of this offering, that same group will continue to beneficially own approximately 72.9% of our outstanding voting stock. Accordingly, even after this offering, these stockholders will have the ability to influence us through this ownership position and significantly affect the outcome of all matters requiring stockholder approval. For example, these stockholders may be able to significantly affect the outcome of elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders. In addition, these stockholders acquired their shares of common stock for substantially less than the price of the shares of common stock being acquired in this offering, and these stockholders may have interests, with respect to their common stock, that are different from those of investors in this offering and the concentration of voting power among these stockholders may have an adverse effect on the price of our common stock.
Source statement; approximately ; source predicate: will continue to beneficially own; primary source clause; full source conditions retained; source scope: of our outstanding voting stock; not an additive ownership partition
Prior to this offering, our executive officers, directors and 5% stockholders beneficially owned approximately 97.84% of our voting stock as of June 30, 2026 and, upon the closing of this offering, that same group will continue to beneficially own approximately 72.9% of our outstanding voting stock. Accordingly, even after this offering, these stockholders will have the ability to influence us through this ownership position and significantly affect the outcome of all matters requiring stockholder approval. For example, these stockholders may be able to significantly affect the outcome of elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders. In addition, these stockholders acquired their shares of common stock for substantially less than the price of the shares of common stock being acquired in this offering, and these stockholders may have interests, with respect to their common stock, that are different from those of investors in this offering and the concentration of voting power among these stockholders may have an adverse effect on the price of our common stock.
Source statement; approximately ; source predicate: will beneficially own; primary source clause; source condition: assuming the conversion of the outstanding convertible notes into 195,425 shares of common stock and including shares underlying vested options exercisable within 60 days, and assuming no exercise of the underwriters’ over-allotment option; source scope: of the voting power of our common stock, assuming the conversion of the outstanding convertible notes into 195,425 shares of common stock and including shares underlying vested options exercisable wi; not an additive ownership partition
Following this offering, Daniel Vlock, our President and Chief Executive Officer, will beneficially own approximately 56.1% of the voting power of our common stock, assuming the conversion of the outstanding convertible notes into 195,425 shares of common stock and including shares underlying vested options exercisable within 60 days, and assuming no exercise of the underwriters’ over-allotment option. As a result, we will be a “controlled company” within the meaning of the NYSE American corporate governance standards. Under these corporate governance standards, a company of which more than 50% of the voting power in the election of directors is held by an individual, group or another company is a “controlled company” and may elect not to comply with certain corporate governance requirements. For example, controlled companies are not required to have:
Exact source ownership column: Shares Beneficially OwnedBefore Offering; Number of Shares; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedBefore Offering; Number of Shares; source holder: Daniel Vlock(2)
Exact source ownership column: Shares Beneficially OwnedAfter Offering; Number of Shares; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedAfter Offering; Number of Shares; source holder: Daniel Vlock(2)
Exact source ownership column: Shares Beneficially OwnedBefore Offering; Number of Shares; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedBefore Offering; Number of Shares; source holder: Peter Werth
Exact source ownership column: Shares Beneficially OwnedAfter Offering; Number of Shares; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedAfter Offering; Number of Shares; source holder: Peter Werth
Exact source ownership column: Shares Beneficially OwnedBefore Offering; Number of Shares; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedBefore Offering; Number of Shares; source holder: Dr. Gerald Pier
Exact source ownership column: Shares Beneficially OwnedAfter Offering; Number of Shares; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedAfter Offering; Number of Shares; source holder: Dr. Gerald Pier
Exact source ownership column: Shares Beneficially OwnedBefore Offering; Number of Shares; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedBefore Offering; Number of Shares; source holder: Gail H. Cassell
Exact source ownership column: Shares Beneficially OwnedAfter Offering; Number of Shares; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedAfter Offering; Number of Shares; source holder: Gail H. Cassell
Exact source ownership column: Shares Beneficially OwnedBefore Offering; Number of Shares; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedBefore Offering; Number of Shares; source holder: Richard Cohen
Exact source ownership column: Shares Beneficially OwnedAfter Offering; Number of Shares; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedAfter Offering; Number of Shares; source holder: Richard Cohen
Exact source ownership column: Shares Beneficially OwnedBefore Offering; Number of Shares; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedBefore Offering; Number of Shares; source holder: Ann MacDougall
Exact source ownership column: Shares Beneficially OwnedAfter Offering; Number of Shares; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedAfter Offering; Number of Shares; source holder: Ann MacDougall
Exact source ownership column: Shares Beneficially OwnedBefore Offering; Percentage; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedBefore Offering; Percentage; source holder: Daniel Vlock(2)
Exact source ownership column: Shares Beneficially OwnedAfter Offering; Percentage; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedAfter Offering; Percentage; source holder: Daniel Vlock(2)
Exact source ownership column: Shares Beneficially OwnedBefore Offering; Percentage; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedBefore Offering; Percentage; source holder: Peter Werth
Exact source ownership column: Shares Beneficially OwnedAfter Offering; Percentage; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedAfter Offering; Percentage; source holder: Peter Werth
Exact source ownership column: Shares Beneficially OwnedBefore Offering; Percentage; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedBefore Offering; Percentage; source holder: Dr. Gerald Pier
Exact source ownership column: Shares Beneficially OwnedAfter Offering; Percentage; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedAfter Offering; Percentage; source holder: Dr. Gerald Pier
Exact source ownership column: Shares Beneficially OwnedBefore Offering; Percentage; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedBefore Offering; Percentage; source holder: Gail H. Cassell
Exact source ownership column: Shares Beneficially OwnedAfter Offering; Percentage; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedAfter Offering; Percentage; source holder: Gail H. Cassell
Exact source ownership column: Shares Beneficially OwnedBefore Offering; Percentage; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedBefore Offering; Percentage; source holder: Richard Cohen
Exact source ownership column: Shares Beneficially OwnedAfter Offering; Percentage; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedAfter Offering; Percentage; source holder: Richard Cohen
Exact source ownership column: Shares Beneficially OwnedBefore Offering; Percentage; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedBefore Offering; Percentage; source holder: Ann MacDougall
Exact source ownership column: Shares Beneficially OwnedAfter Offering; Percentage; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedAfter Offering; Percentage; source holder: Ann MacDougall
Exact source ownership column: Shares Beneficially OwnedBefore Offering; Number of Shares; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedBefore Offering; Number of Shares; source holder: Christine de los Reyes
Exact source ownership column: Shares Beneficially OwnedAfter Offering; Number of Shares; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedAfter Offering; Number of Shares; source holder: Christine de los Reyes
Exact source ownership column: Shares Beneficially OwnedBefore Offering; Number of Shares; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedBefore Offering; Number of Shares; source holder: William W. Chin
Exact source ownership column: Shares Beneficially OwnedAfter Offering; Number of Shares; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedAfter Offering; Number of Shares; source holder: William W. Chin
Exact source ownership column: Shares Beneficially OwnedBefore Offering; Number of Shares; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedBefore Offering; Number of Shares; source holder: Thomas T. Thomas
Exact source ownership column: Shares Beneficially OwnedAfter Offering; Number of Shares; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedAfter Offering; Number of Shares; source holder: Thomas T. Thomas
Exact source ownership column: Shares Beneficially OwnedBefore Offering; Number of Shares; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedBefore Offering; Number of Shares; source holder: All Directors, Executive Officers and Director Nominees as a group (7 persons)
Exact source ownership column: Shares Beneficially OwnedAfter Offering; Number of Shares; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedAfter Offering; Number of Shares; source holder: All Directors, Executive Officers and Director Nominees as a group (7 persons)
Exact source ownership column: Shares Beneficially OwnedBefore Offering; Percentage; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedBefore Offering; Percentage; source holder: Christine de los Reyes
Exact source ownership column: Shares Beneficially OwnedAfter Offering; Percentage; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedAfter Offering; Percentage; source holder: Christine de los Reyes
Exact source ownership column: Shares Beneficially OwnedBefore Offering; Percentage; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedBefore Offering; Percentage; source holder: William W. Chin
Exact source ownership column: Shares Beneficially OwnedAfter Offering; Percentage; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedAfter Offering; Percentage; source holder: William W. Chin
Exact source ownership column: Shares Beneficially OwnedBefore Offering; Percentage; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedBefore Offering; Percentage; source holder: Thomas T. Thomas
Exact source ownership column: Shares Beneficially OwnedAfter Offering; Percentage; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedAfter Offering; Percentage; source holder: Thomas T. Thomas
Exact source ownership column: Shares Beneficially OwnedBefore Offering; Percentage; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedBefore Offering; Percentage; source holder: All Directors, Executive Officers and Director Nominees as a group (7 persons)
Exact source ownership column: Shares Beneficially OwnedAfter Offering; Percentage; holders may overlap; not an additive partition
Raw source column: Shares Beneficially OwnedAfter Offering; Percentage; source holder: All Directors, Executive Officers and Director Nominees as a group (7 persons)
Economic ownership
A chart needs complete, non-overlapping economic interests on one date and share basis. The disclosed holder figures remain in the table.
Share supply
Source lock-up conditions
Literal month restriction; after date of this prospectus; full conditions and exceptions remain in the source paragraph
| Measure | Reported value |
|---|---|
| Our executive officers and directorsAfter date of this prospectus · Source conditions apply | 12 months |
| Our executive officers and directorsAfter date of this prospectus · Source conditions apply | 12 months |
| our stockholdersAfter date of this prospectus · Source conditions apply | 6 months |
| our stockholdersAfter date of this prospectus · Source conditions apply | 6 months |
Source and calculation
Our executive officers and directors have agreed with the underwriters not to sell, transfer or dispose of any shares or similar securities for a period of 12 months from the date of this prospectus, and all of our stockholders have agreed with the underwriters not to sell, transfer or dispose of any shares or similar securities for a period of 6 months from the date of this prospectus. For additional information regarding our arrangement with the underwriters, please see “Underwriting.”
SEC lock-up paragraph; source 214766:215682; SHA256 66834fcf3d774b620abe544f6b3f3ff7140ab2dfc3ccbdc777b210153f0c5981 ↗Our executive officers and directors have agreed with the underwriters not to sell, transfer or dispose of any shares or similar securities for a period of 12 months from the date of this prospectus, and all of our stockholders have agreed with the underwriters not to sell, transfer or dispose of any shares or similar securities for a period of 6 months from the date of this prospectus. For additional information regarding our arrangement with the underwriters, please see “Underwriting.”
SEC table 8 row 7; source 199480:219857; SHA256 397ebe6f327438080add9f1f3b80d41d575c0b81807d291d5b71848035078430 ↗Our executive officers and directors have agreed with the underwriters not to sell, transfer or dispose of any shares or similar securities for a period of 12 months from the date of this prospectus, and all of our stockholders have agreed with the underwriters not to sell, transfer or dispose of any shares or similar securities for a period of 6 months from the date of this prospectus. For additional information regarding our arrangement with the underwriters, please see “Underwriting.”
SEC lock-up paragraph; source 214766:215682; SHA256 66834fcf3d774b620abe544f6b3f3ff7140ab2dfc3ccbdc777b210153f0c5981 ↗Our executive officers and directors have agreed with the underwriters not to sell, transfer or dispose of any shares or similar securities for a period of 12 months from the date of this prospectus, and all of our stockholders have agreed with the underwriters not to sell, transfer or dispose of any shares or similar securities for a period of 6 months from the date of this prospectus. For additional information regarding our arrangement with the underwriters, please see “Underwriting.”
SEC table 8 row 7; source 199480:219857; SHA256 397ebe6f327438080add9f1f3b80d41d575c0b81807d291d5b71848035078430 ↗Source lock-up conditions
| Measure | Reported value |
|---|---|
| We, along with our directors, executive officers and all of our other stockholders and option holders,After date of this prospectus · Source conditions apply | 365 days |
| the warrantsAfter effective date of the registration statement · Source conditions apply | 180 days |
Source and calculation
We, along with our directors, executive officers and all of our other stockholders and option holders, have agreed with the underwriters that for a period of 365 days with respect to us, our directors and executive officers and 180 days with respect to all of our other stockholders and option holders, after the date of this prospectus, subject to specified exceptions as detailed further in the section entitled “Underwriting,” we or they will not, except with the prior written consent of ThinkEquity offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to sale of, or otherwise dispose of or transfer any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, request or demand that we file a registration statement related to our common stock or enter into any swap or other agreement that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock. All of our stockholders are subject to a market stand-off agreement with us which imposes similar restrictions.
SEC lock-up paragraph; source 3001250:3002859; SHA256 7be8ad8253006ced8e7bf463ae7934930a9af07b5daffe51a27c5d7820886c96 ↗The Representative’s Warrants have been deemed compensation by FINRA and are therefore subject to a 180-day lock-up pursuant to FINRA Rule 5110(e)(1). The Representative (or permitted assignees under Rule 5110(e)(2)) will not sell, transfer, assign, pledge, or hypothecate these warrants or the securities underlying these warrants, nor will they engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the warrants or the underlying securities for a period of 180 days from the effective date of the registration statement. In addition, the warrants provide for registration rights upon request, in certain cases. The one-time demand registration right provided will not be greater than five years from the effective date of the registration statement in compliance with FINRA Rule 5110(g)(8)(C). The unlimited piggyback registration right provided will not be greater than seven years from the effective date of the registration statement in compliance with FINRA Rule 5110(g)(8)(D). We will bear all fees and expenses attendant to registering the securities issuable on exercise of the warrants other than underwriting commissions incurred and payable by the holders. The exercise price and number of shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend or our recapitalization, reorganization, merger or consolidation. However, the warrant exercise price or underlying shares will not be adjusted for issuances of shares of common stock at a price below the warrant exercise price.
SEC lock-up paragraph; source 3085884:3088019; SHA256 fe72cc4c6049f427c0bcb8b546d3f8a17e44c85d13665285312a8ee437e54eb2 ↗Conditional lock-up timeline
Conditional lock-up timeline
Eligibility is not a sale. Release conditions, holder groups and exceptions remain separate.
date of this prospectus
- our stockholdersOur executive officers and directors have agreed with the underwriters not to sell, transfer or dispose of any shares or similar securities for a period of 12 months from the date of this prospectus, and all of our stockholders have agreed with the underwriters not to sell, transfer or dispose of any shares or similar securities for a period of 6 months from the date of this prospectus. For additional information regarding our arrangement with the underwriters, please see “Underwriting.”
- Our executive officers and directorsOur executive officers and directors have agreed with the underwriters not to sell, transfer or dispose of any shares or similar securities for a period of 12 months from the date of this prospectus, and all of our stockholders have agreed with the underwriters not to sell, transfer or dispose of any shares or similar securities for a period of 6 months from the date of this prospectus. For additional information regarding our arrangement with the underwriters, please see “Underwriting.”
| Holder / event | Term / date | Conditions |
|---|---|---|
| Our executive officers and directors | 12 months | Our executive officers and directors have agreed with the underwriters not to sell, transfer or dispose of any shares or similar securities for a period of 12 months from the date of this prospectus, and all of our stockholders have agreed with the underwriters not to sell, transfer or dispose of any shares or similar securities for a period of 6 months from the date of this prospectus. For additional information regarding our arrangement with the underwriters, please see “Underwriting.” |
| our stockholders | 6 months | Our executive officers and directors have agreed with the underwriters not to sell, transfer or dispose of any shares or similar securities for a period of 12 months from the date of this prospectus, and all of our stockholders have agreed with the underwriters not to sell, transfer or dispose of any shares or similar securities for a period of 6 months from the date of this prospectus. For additional information regarding our arrangement with the underwriters, please see “Underwriting.” |
date of this prospectus
- We, along with our directors, executive officers and all of our other stockholders and option holders,We, along with our directors, executive officers and all of our other stockholders and option holders, have agreed with the underwriters that for a period of 365 days with respect to us, our directors and executive officers and 180 days with respect to all of our other stockholders and option holders, after the date of this prospectus, subject to specified exceptions as detailed further in the section entitled “Underwriting,” we or they will not, except with the prior written consent of ThinkEquity offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to sale of, or otherwise dispose of or transfer any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, request or demand that we file a registration statement related to our common stock or enter into any swap or other agreement that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock. All of our stockholders are subject to a market stand-off agreement with us which imposes similar restrictions.
| Holder / event | Term / date | Conditions |
|---|---|---|
| We, along with our directors, executive officers and all of our other stockholders and option holders, | 365 days | We, along with our directors, executive officers and all of our other stockholders and option holders, have agreed with the underwriters that for a period of 365 days with respect to us, our directors and executive officers and 180 days with respect to all of our other stockholders and option holders, after the date of this prospectus, subject to specified exceptions as detailed further in the section entitled “Underwriting,” we or they will not, except with the prior written consent of ThinkEquity offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to sale of, or otherwise dispose of or transfer any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, request or demand that we file a registration statement related to our common stock or enter into any swap or other agreement that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock. All of our stockholders are subject to a market stand-off agreement with us which imposes similar restrictions. |
effective date of the registration statement
- the warrantsThe Representative’s Warrants have been deemed compensation by FINRA and are therefore subject to a 180-day lock-up pursuant to FINRA Rule 5110(e)(1). The Representative (or permitted assignees under Rule 5110(e)(2)) will not sell, transfer, assign, pledge, or hypothecate these warrants or the securities underlying these warrants, nor will they engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the warrants or the underlying securities for a period of 180 days from the effective date of the registration statement. In addition, the warrants provide for registration rights upon request, in certain cases. The one-time demand registration right provided will not be greater than five years from the effective date of the registration statement in compliance with FINRA Rule 5110(g)(8)(C). The unlimited piggyback registration right provided will not be greater than seven years from the effective date of the registration statement in compliance with FINRA Rule 5110(g)(8)(D). We will bear all fees and expenses attendant to registering the securities issuable on exercise of the warrants other than underwriting commissions incurred and payable by the holders. The exercise price and number of shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend or our recapitalization, reorganization, merger or consolidation. However, the warrant exercise price or underlying shares will not be adjusted for issuances of shares of common stock at a price below the warrant exercise price.
| Holder / event | Term / date | Conditions |
|---|---|---|
| the warrants | 180 days | The Representative’s Warrants have been deemed compensation by FINRA and are therefore subject to a 180-day lock-up pursuant to FINRA Rule 5110(e)(1). The Representative (or permitted assignees under Rule 5110(e)(2)) will not sell, transfer, assign, pledge, or hypothecate these warrants or the securities underlying these warrants, nor will they engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the warrants or the underlying securities for a period of 180 days from the effective date of the registration statement. In addition, the warrants provide for registration rights upon request, in certain cases. The one-time demand registration right provided will not be greater than five years from the effective date of the registration statement in compliance with FINRA Rule 5110(g)(8)(C). The unlimited piggyback registration right provided will not be greater than seven years from the effective date of the registration statement in compliance with FINRA Rule 5110(g)(8)(D). We will bear all fees and expenses attendant to registering the securities issuable on exercise of the warrants other than underwriting commissions incurred and payable by the holders. The exercise price and number of shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend or our recapitalization, reorganization, merger or consolidation. However, the warrant exercise price or underlying shares will not be adjusted for issuances of shares of common stock at a price below the warrant exercise price. |
Basis and evidence
Our executive officers and directors have agreed with the underwriters not to sell, transfer or dispose of any shares or similar securities for a period of 12 months from the date of this prospectus, and all of our stockholders have agreed with the underwriters not to sell, transfer or dispose of any shares or similar securities for a period of 6 months from the date of this prospectus. For additional information regarding our arrangement with the underwriters, please see “Underwriting.”
SEC lock-up paragraph; source 214766:215682; SHA256 66834fcf3d774b620abe544f6b3f3ff7140ab2dfc3ccbdc777b210153f0c5981 ↗Our executive officers and directors have agreed with the underwriters not to sell, transfer or dispose of any shares or similar securities for a period of 12 months from the date of this prospectus, and all of our stockholders have agreed with the underwriters not to sell, transfer or dispose of any shares or similar securities for a period of 6 months from the date of this prospectus. For additional information regarding our arrangement with the underwriters, please see “Underwriting.”
SEC lock-up paragraph; source 214766:215682; SHA256 66834fcf3d774b620abe544f6b3f3ff7140ab2dfc3ccbdc777b210153f0c5981 ↗We, along with our directors, executive officers and all of our other stockholders and option holders, have agreed with the underwriters that for a period of 365 days with respect to us, our directors and executive officers and 180 days with respect to all of our other stockholders and option holders, after the date of this prospectus, subject to specified exceptions as detailed further in the section entitled “Underwriting,” we or they will not, except with the prior written consent of ThinkEquity offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to sale of, or otherwise dispose of or transfer any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, request or demand that we file a registration statement related to our common stock or enter into any swap or other agreement that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock. All of our stockholders are subject to a market stand-off agreement with us which imposes similar restrictions.
SEC lock-up paragraph; source 3001250:3002859; SHA256 7be8ad8253006ced8e7bf463ae7934930a9af07b5daffe51a27c5d7820886c96 ↗The Representative’s Warrants have been deemed compensation by FINRA and are therefore subject to a 180-day lock-up pursuant to FINRA Rule 5110(e)(1). The Representative (or permitted assignees under Rule 5110(e)(2)) will not sell, transfer, assign, pledge, or hypothecate these warrants or the securities underlying these warrants, nor will they engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the warrants or the underlying securities for a period of 180 days from the effective date of the registration statement. In addition, the warrants provide for registration rights upon request, in certain cases. The one-time demand registration right provided will not be greater than five years from the effective date of the registration statement in compliance with FINRA Rule 5110(g)(8)(C). The unlimited piggyback registration right provided will not be greater than seven years from the effective date of the registration statement in compliance with FINRA Rule 5110(g)(8)(D). We will bear all fees and expenses attendant to registering the securities issuable on exercise of the warrants other than underwriting commissions incurred and payable by the holders. The exercise price and number of shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend or our recapitalization, reorganization, merger or consolidation. However, the warrant exercise price or underlying shares will not be adjusted for issuances of shares of common stock at a price below the warrant exercise price.
SEC lock-up paragraph; source 3085884:3088019; SHA256 fe72cc4c6049f427c0bcb8b546d3f8a17e44c85d13665285312a8ee437e54eb2 ↗Financial quality
Bars compare absolute amounts within each measure. Each measure has its own scale.
Net income / (loss)
$ · Annual values as reportedOperating cash flow
$ · Annual values as reported| Calculation | FY2024 | FY2025 |
|---|---|---|
| Net income / (loss) | ($3,060,624) | ($2,608,394) |
| Operating cash flow | ($481,234) | ($1,140,128) |
| Calculation | Reported value |
|---|---|
| Current assets2026-06-30 · Unaudited | $981,003 |
| Current assets2025-12-31 | $911,886 |
| Total assets2026-06-30 · Unaudited | $981,003 |
| Total assets2025-12-31 | $911,886 |
| Current liabilities2026-06-30 · Unaudited | $5,036,726 |
| Current liabilities2025-12-31 | $6,203,025 |
| Total liabilities2026-06-30 · Unaudited | $7,403,393 |
| Total liabilities2025-12-31 | $7,003,025 |
| Total equity / (deficit)2026-06-30 · Unaudited | ($6,422,390) |
| Total equity / (deficit)2025-12-31 | ($6,091,139) |
| General and administrative expenses3M ended 2026-06-30 · Unaudited | $256,981 |
| General and administrative expenses3M ended 2025-06-30 · Unaudited | $618,514 |
| General and administrative expenses6M ended 2026-06-30 · Unaudited | $604,164 |
| General and administrative expenses6M ended 2025-06-30 · Unaudited | $1,277,540 |
| Net income / (loss)3M ended 2026-06-30 · Unaudited | ($541,829) |
| Net income / (loss)3M ended 2025-06-30 · Unaudited | ($746,042) |
| Net income / (loss)6M ended 2026-06-30 · Unaudited | ($1,010,625) |
| Net income / (loss)6M ended 2025-06-30 · Unaudited | ($1,529,267) |
| Operating cash flow6M ended 2026-06-30 · Unaudited | ($530,883) |
| Operating cash flow6M ended 2025-06-30 · Unaudited | ($626,962) |
| Current assets2024-12-31 | $1,152,014 |
| Total assets2024-12-31 | $1,152,014 |
| Current liabilities2024-12-31 | $6,078,307 |
| Total liabilities2024-12-31 | $6,278,307 |
| General and administrative expensesFY2025 | $2,118,730 |
| General and administrative expensesFY2024 | $2,590,815 |
Basis and evidence
Financial quality and runway
Financial quality and runway
Latest supplied financial information covers six months ended June 30, 2026 and balance-sheet data as of June 30, 2026. The company reports no product-sale revenue in the supplied evidence, a $1.01 million net loss for the latest six months, $97,586 cash, $1.45 million notes payable, and a going-concern warning.
EvidenceFinancial review 1Net loss was $1,010,625 for the six months ended June 30, 2026, compared with $1,529,267 for the comparable 2025 period.
+
Net loss was $1,010,625 for the six months ended June 30, 2026, compared with $1,529,267 for the comparable 2025 period.
EvidenceFinancial review 22025 and 2024 net losses were $2,608,394 and $3,060,624, respectively; accumulated deficit was $17,723,578 at June 30, 2026.
+
2025 and 2024 net losses were $2,608,394 and $3,060,624, respectively; accumulated deficit was $17,723,578 at June 30, 2026.
EvidenceFinancial review 3The independent auditor’s report for 2025 included an explanatory paragraph regarding substantial doubt about going concern.
+
The independent auditor’s report for 2025 included an explanatory paragraph regarding substantial doubt about going concern.
MATERIAL CHANGES
The latest material signals and their investor impact are shown below.
Why it mattersThe current filing uses June 30/August 31, 2026 data, increases assumed post-offering shares from 8,349,352 to 8,350,506, and changes pro forma cash from $490,278 to $97,586 before offering proceeds.
Evidence · The Offering; CapitalizationS-1/A0001213900-26-101026 ↗
Loading filing history…
Neither AV0328 nor F598 is approved for commercial sale, and the company has not demonstrated completion of pivotal development or commercialization.
- Evidence
- Risk Factors Summary ↗
Regulators may require field efficacy trials rather than relying on surrogate OPK endpoints for AV0328.
- Evidence
- Risk Factors Summary ↗
The company relies on Bharat as a single vaccine CMO and may face costly, time-consuming transition if supply is interrupted.
- Evidence
- Risk Factors ↗
The company reports substantial doubt about going concern and may need additional capital even after the offering.
- Evidence
- Risk Factors ↗